How to buy Heat Biologics shares

Own Heat Biologics shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Heat Biologics, Inc is a biotechnology business with stocks listed in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$6.44 – a decrease of 2.57% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Heat Biologics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Heat Biologics. Find the share by name or ticker symbol: HTBX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heat Biologics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$6.44, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Heat Biologics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Heat Biologics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Heat Biologics share price

Use our graph to track the performance of HTBX stocks over time.

Heat Biologics shares at a glance

Information last updated 2021-06-10.
52-week rangeUS$4.9 - US$30.1
50-day moving average US$6.5365
200-day moving average US$7.2184
Target priceUS$24.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-0.654

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Heat Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Heat Biologics price performance over time

Historical closes compared with the last close of $6.44

1 week (2021-06-08) -6.67%
1 month (2021-05-14) 8.24%
3 months (2021-03-15) -27.15%
6 months (2020-12-15) 19.70%
1 year (2020-06-15) 16.90%
2 years (2019-06-14) 23.37%
3 years (2018-06-15) -58.37%
5 years (2016-06-15) 52.52%

Heat Biologics financials

Revenue TTM US$2.6 million
Gross profit TTM US$-9,990,926
Return on assets TTM -18.8%
Return on equity TTM -33.91%
Profit margin 0%
Book value 5.462
Market capitalisation US$173 million

TTM: trailing 12 months

Shorting Heat Biologics shares

There are currently 2.3 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 5.9% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.

Heat Biologics's "short interest ratio" (SIR)

Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 348794.7761194). Heat Biologics's SIR currently stands at 6.7. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 6700 shares are currently held short.

However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 100 shares are currently held short) or 0.1029% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 103 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.

Find out more about how you can short Heat Biologics stock.

Heat Biologics share dividends

We're not expecting Heat Biologics to pay a dividend over the next 12 months.

Have Heat Biologics's shares ever split?

Heat Biologics's shares were split on a 1:7 basis on 10 December 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.

Heat Biologics share price volatility

Over the last 12 months, Heat Biologics's shares have ranged in value from as little as US$4.9 up to US$30.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.2848. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).

Heat Biologics overview

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform